Výsledky vyhledávání

Perspective on This Article from Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

Autor: Ethan Dmitrovsky, Samuel Waxman, Jonathan M. Kurie, Sarah J. Freemantle, Xi Liu, James R. Rigas, William Nugent, Cherie P. Erkmen, David Johnstone, Marc Seltzer, Gregory J. Tsongalis, Alexander M. Busch, Vincent Memoli, Fabrizio Galimberti, Jobin Cyrus, Tian Ma, Konstantin H. Dragnev

Perspective on This Article from Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04de993e29596306e23331f207ed8327
https://doi.org/10.1158/1940-6207.22524630.v1

Zobrazit plný text záznamu

Supplementary Figure S1 from Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

Supplementary Figure S1 from Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751775a8faff2ebd75a8a5d9f7a22def
https://doi.org/10.1158/1940-6207.22524627

Zobrazit plný text záznamu

Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor

Publikováno v: Cancer Research. 82:CT557-CT557

Background: Safe, effective treatment options for advanced melanoma that progressed on a PD-1/PD-L1 inhibitor is an unmet medical need. Results of the phase 1b KEYNOTE-029 trial showed promising antitumor activity in advanced melanoma with pembro com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7f00172a4f14e153170f48ab8ff2d38
https://doi.org/10.1158/1538-7445.am2022-ct557

Zobrazit plný text záznamu

Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study

Publikováno v: Journal of Clinical Oncology. 37:2558-2558

2558 Background: An ongoing multicenter, open-label, phase 1 study of the anti–CTLA-4 antibody MK-1308 in combination with pembro in advanced solid tumors (NCT03179436) revealed a manageable safety profile and promising efficacy in pts with first-l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2d9f45825fb77f976f8474ec6da92f0
https://doi.org/10.1200/jco.2019.37.15_suppl.2558

Zobrazit plný text záznamu

Racial Differences in the Incidence of Mesenchymal Tumors Associated with EWSR1 Translocation

Autor: Jobin Cyrus, John Neuhaus, Katherine K. Matthay, Steven G. DuBois, Jennifer Worch, Robert E. Goldsby

Publikováno v: Cancer Epidemiology, Biomarkers & Prevention. 20:449-453

Background: The incidence of Ewing sarcoma varies by race, with very low rates among persons of African and East Asian ancestry. The incidence by race of other mesenchymal tumors that also harbor EWSR1 translocations has not been studied. Methods: Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f82e94c3e054e8871f723e959093ddf
https://doi.org/10.1158/1055-9965.epi-10-1170

Zobrazit plný text záznamu

Predictors of Acute Chemotherapy-Associated Toxicity in Patients with Ewing Sarcoma

Autor: John Neuhaus, Florette K. Hazard, Jeremy Sharib, Robert E. Goldsby, Jobin Cyrus, Steven G. DuBois, Neyssa Marina, Andrew E. Horvai, Katherine K. Matthay

Background Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue of children and young adults. Patients with ES are treated with intensive chemotherapy regimens. We describe predictors of acute chemotherapy-associated toxicity in this popul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f479b02ff9f6db97fedbb0ec1c9ba4b9
https://europepmc.org/articles/PMC3310949/

Zobrazit plný text záznamu

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

Autor: Samuel Waxman, Ethan Dmitrovsky, James R. Rigas, Tian Ma, Cherie P. Erkmen, Gregory J. Tsongalis, William C. Nugent, Vincent A. Memoli, Jobin Cyrus, Alexander M. Busch, Marc Seltzer, Sarah J. Freemantle, Xi Liu, David W. Johnstone, Jonathan M. Kurie, Fabrizio Galimberti, Konstantin H. Dragnev

Publikováno v: Cancer prevention research (Philadelphia, Pa.). 4(6)

The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f30daae32a62c6d770e38b67454dbd49
https://pubmed.ncbi.nlm.nih.gov/21636543

Zobrazit plný text záznamu

Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations

Autor: Marc Seltzer, Jobin Cyrus, Alexander M. Busch, Vincent A. Memoli, Xi Liu, James R. Rigas, Samuel Waxman, Sarah J. Freemantle, Ethan Dmitrovsky, Fabrizio Galimberti, Tian Ma, Cherie P. Erkmen, Konstantin H. Dragnev, Gregory J. Tsongalis, William C. Nugent, David W. Johnstone, Jonathan M. Kurie

Publikováno v: Cancer Research. 71:LB-412

Lung cancer is the leading cause of cancer-related mortality in the United States. Improved ways to treat and prevent lung cancer are needed. Increased epidermal growth factor receptor (EGFR) expression frequently occurs in lung carcinogenesis. Treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a8a1d5c7fb593954a23e07439c23013
https://doi.org/10.1158/1538-7445.am2011-lb-412

Zobrazit plný text záznamu

Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene

Autor: Ethan Dmitrovsky, W. M. Disalvo, Jobin Cyrus, Konstantin H. Dragnev, James R. Rigas

Publikováno v: Journal of Clinical Oncology. 27:8101-8101

8101 Background: Studies of the nonclassical retinoid bexarotene (B) alone or in combination with chemotherapy have revealed improved survival for a subset of NSCLC patients (pts) who developed hypertrigyceridemia despite treatment with antilipid age

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7b41f7ff56208f91ff354b7ff165002
https://doi.org/10.1200/jco.2009.27.15_suppl.8101

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání